Nasdaq Correction Have You Worried? 3 Unstoppable Stocks to Buy Hand Over Fist Right Now.

Oscar Health began 2026 with 3.4 million members and guides $250M–$450M in income from operations for 2026, trading at a ~$3.3B market cap — positioning it as a cheaply valued, growth-stage ACA insurer if profitability is achieved. Adyen reported 21% revenue growth y/y (constant currency) in H2 with 55% EBITDA margins, but its shares are off >50% from recent highs and the stock trades at a P/E of ~26 (its lowest ever). Remitly grew revenue 26% y/y to $442M last quarter with a record 9% operating margin, a $3.1B market cap and a ~69% decline from all-time highs, while expanding products (SMB transfers, digital wallets, BNPL-style “send now, pay later”). The broader market is in a Nasdaq-100 correction (>10% off highs) amid Iran-related oil/inflation concerns, creating a risk-off technical backdrop that may present selective buying opportunities in secular winners.

Analysis

Geopolitical stress in the Middle East creates an outsized second‑order risk to cross‑border money flows: remittance volumes from energy‑exporting corridors can compress within weeks if payrolls or guest‑worker repatriations accelerate, while FX volatility temporarily widens spreads and margins for digital remitters. That asymmetry means a company with concentrated corridor exposure can see revenue and operating margin swings larger than their top‑line growth would imply; FX hedging and corridor diversification become as important as customer acquisition cost metrics.

Oscar’s technology‑forward distribution and direct relationship with members reduce per‑member acquisition and claims management friction, which should compound over several quarters as CRM and telehealth features mature. The principal reversals that would meaningfully hurt the thesis are regulatory shifts (subsidy design, risk‑adjustment tweaks) or a sharp uptick in provider price inflation that outpaces the insurer’s ability to reprice—both of which operate on a 3–12 month policy and contracting cadence.

Adyen’s fixed‑cost processing backbone gives it optionality to monetize data and embed higher‑margin services into enterprise contracts, but regulatory moves (interchange caps, BIN unbundling) and verticalized competitors embedding payments into stack providers are credible medium‑term threats. For all three businesses, focus on cadence of product rollouts and gross margin per transaction (not just volume growth): that per‑unit economics line will determine whether current share‑gains convert to durable free cash flow over 12–24 months.

Key Decisions for Investors

• Long OSCR via 9–15 month call LEAPs (buy calls 25–35% OTM) sized 2–3% of equity book: asymmetric upside if retention/pricing holds; defined premium risk if regulatory/subsidy noise forces churn—target 2.5x option payoff or cut at 100% premium loss.
• Pair trade: long ADYEY stock or 12–18 month call spread (25% OTM) vs short PYPL (size 0.5–1x notional of ADYEY long) for 6–12 months — play enterprise payments stickiness against consumer wallet re‑rating. Expect 20–40% relative outperformance; stop‑loss at 15% adverse move on the pair.
• Hedge Remitly exposure with a directional but capped downside: buy RELY 6–12 month put spread (e.g., buy 25% OTM put / sell 40% OTM put) sized to cover 50–75% of notional exposure. Rationale: limits premium paid while protecting against corridor shocks or FX shocks in a 1–6 month window; reward if remittance corridors contract, cost if normalizing.
• Macro/FX hedge: increase short‑dated USD‑EM FX protection (selective long USD via futures or UUP, or buy puts on high‑beta remittance‑receiving EMFX) for 1–3 months to protect portfolio from rapid remittance flow contraction driven by regional geopolitics. Expect this to cost carry but materially reduce downside tail from simultaneous falls in remittance revenues and EM FX.